References
- Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med. 2004;351:1655–1665.
- Gaine SP, Rubin LJ. Primary pulmonary hypertension. Lancet. 1998;352:719–725.
- Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med. 2004;351:1425–1436.
- Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation. 2010;122:156–163.
- Humbert M, Lau EMT, Montani D, et al. Advances in therapeutic interventions for patients with pulmonary arterial hypertension. Circulation. 2014;130:2189–2208.
- Archer SL, Michelakis ED. Phosphodiesterase Type 5 inhibitors for pulmonary arterial hypertension. N Engl J Med. 2009;361:1864–1871.
- Galiè N, Humbert M, Vachiery J-L, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37:67–119.
- Badagliacca R, D’Alto M, Ghio S, et al. Risk reduction and hemodynamics with initial combination therapy in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2021;203:484–492.
- Bouzina H, Rådegran G, Butler O, et al. Longitudinal changes in risk status in pulmonary arterial hypertension. ESC Heart Fail. 2021;8:680–690.
- Hoeper MM, Al-Hiti H, Benza RL, et al. Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial. Lancet Respir Med. 2021;9:573–584.
- State Institute for Drug Control [Internet]. [ cited 2021 Oct 1]. Available from: https://www.sukl.eu/modules/procedures/detail.php?spzn=SUKLS298134%2F2016
- Song F. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ. 2003;326:472.
- Bucher HC, Guyatt GH, Griffith LE, et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50:683–691.
- Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR task force on indirect treatment comparisons good research practices: part 1. Value Health. 2011;14:417–428.
- Fu W, He W, Li Y, et al. Efficacy and safety of novel-targeted drugs in the treatment of pulmonary arterial hypertension: a Bayesian network meta-analysis. Drug Deliv. 2021;28:1007–1019.
- Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.
- Sitbon O, Channick R, Chin KM, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015;373:2522–2533.
- Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 2005.
- ISPOR - Good Practices for Outcomes Research [Internet]. [cited 2021 Dec 12]. Available from: http://www.ispor.org/heor-resources/good-practices-for-outcomes-research
- Husereau D, Drummond M, Augustovski F, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 explanation and elaboration: a report of the ISPOR CHEERS II good practices task force. Value Health. 2022;25:10–31.
- Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
- Jain S, Khera R, Girotra S, et al. Comparative effectiveness of pharmacologic interventions for pulmonary arterial hypertension: a systematic review and network meta-analysis. Chest. 2017;151:90–105.
- Badiani B, Messori A. Targeted treatments for pulmonary arterial hypertension: interpreting outcomes by network meta-analysis. Heart Lung Circ. 2016;25:46–52.
- State Institute for Drug Control [Internet]. [cited 2021 Dec 12]. Available from: https://www.sukl.eu/modules/procedures/detail.php?spzn=SUKLS159377%2F2021
- Ghofrani H-A, D’Armini AM, Grimminger F, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med. 2013;369:319–329.
- Ghofrani H-A, Grimminger F, Grünig E, et al. Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial. Lancet Respir Med. 2016;4:361–371.
- Rubin LJ, Galiè N, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2). Eur Respir J. 2015;45:1303–1313.
- Wang S, Yu M, Zheng X, et al. A Bayesian network meta-analysis on the efficacy and safety of eighteen targeted drugs or drug combinations for pulmonary arterial hypertension. Drug Deliv. 2018;25:1898–1909.
- Simonneau G, Torbicki A, Hoeper MM, et al. Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J. 2012;40:874–880.
- Grinnan D, Kang L, DeWilde C, et al. Prediction of patient outcomes through social determinants of health: the Pulmonary Hypertension Association Registry (PHAR) evaluation. Pulm Circ. 2022;12:e12120.
- Bernardo RJ, Lu D, Ramirez RL, et al. Hispanic ethnicity and social determinants of health in pulmonary arterial hypertension: the Pulmonary Hypertension Association Registry. Ann Am Thorac Soc. 2022;19:1459–1468.
- Regulation of prices and reimbursements for pharmaceuticals. State Institute for Drug Control [Internet]. [cited 2022 Sep 03]. Available from: http://www.sukl.eu/medicines/regulation-of-prices-and-reimbursements-for-pharmaceuticals?highlightWords=sp-cau-028
- EMA - Uptravi (selexipag) [Internet]. [cited 2022 Sep 14]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/uptravi
- EMA - Adempas (riociguat) [Internet]. [cited 2022 Sep 14]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/adempas
- State Institute for Drug Control [Internet]. [cited 2022 Sep 14]. Available from: https://www.sukl.cz/leciva/seznam-referencnich-zdroju-sukl
- State Institute for Drug Control [Internet]. [cited 2022 Sep 03]. Available from: https://www.sukl.cz/modules/medication/detail.php?code=0194870&tab=prices